Lineage Cell Therapeutics, Inc.

Equities

LCTX

US53566P1093

Biotechnology & Medical Research

Market Closed - Nyse 04:00:00 2024-03-01 pm EST 5-day change 1st Jan Change
1.11 USD +6.73% Intraday chart for Lineage Cell Therapeutics, Inc. +7.77% +1.83%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Lineage Announces FDA Clearance of IND Amendment for Opc1 Cell Transplant for the Treatment of Spinal Cord Injury CI
Lineage Cell Therapeutics Launches $14 Million Registered Direct Offering MT
Lineage Announces Submission of OPC1 Investigational New Drug Amendment for Treatment of Chronic and Subacute Spinal Cord Injury CI
Transcript : Lineage Cell Therapeutics, Inc., Q3 2023 Earnings Call, Nov 09, 2023
Lineage Cell Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Earnings Flash (LCTX) LINEAGE CELL THERAPEUTICS Posts Q3 Revenue $1.2M, vs. Street Est of $2.6M MT
Lineage Cell Therapeutics, Inc. Announces to Present Rg6501 Phase 1/2A Results to Be Featured At Eyecelerator At 2023 American Academy of Ophthalmology CI
Lineage Cell Therapeutics, Inc. Announces Results of Imaging Analyses Demonstrating Rapid Improvement in Outer Retinal Structure from Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration CI
Lineage Cell Therapeutics, Inc. Announces Results of Imaging Analyses Demonstrating Rapid Improvement in Outer Retinal Structure from Patients Enrolled in A Phase 1/2A Clinical Study of RG6501 CI
EARNINGS: R&Q Insurance loss swells, Jade Road still selling assets AN
Lineage Cell Therapeutics, Inc. Announces the Results of Imaging Analyses Demonstrating Evidence of Rapid Improvement in Outside Retinal Structure from A Phase 1/2A Clinical Study of Rg6501 CI
Transcript : Lineage Cell Therapeutics, Inc., Q2 2023 Earnings Call, Aug 10, 2023
Earnings Flash (LCTX) LINEAGE CELL THERAPEUTICS Reports Q2 Revenue $3.2M, vs. Street Est of $2.2M MT
Lineage Cell Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Lineage Cell Therapeutics, Cancer Research UK Report 'Encouraging' Results in Lung Cancer Trial MT
Lineage Cell Therapeutics and Cancer Research UK Reports Topline Phase 1 Study Results With VAC2 for the Treatment of Advanced Non-small Cell Lung Cancer CI
Lineage Cell Therapeutics, Inc.(NYSEAM:LCTX) added to Russell 2500 Index CI
Lineage Cell Therapeutics, Inc.(NYSEAM:LCTX) added to Russell Small Cap Completeness Index CI
Lineage Cell Therapeutics, Inc.(NYSEAM:LCTX) added to Russell 3000E Index CI
Lineage Cell Therapeutics, Inc.(NYSEAM:LCTX) added to Russell 3000 Index CI
Lineage Cell Therapeutics, Inc.(NYSEAM:LCTX) added to Russell 3000E Growth Index CI
Lineage Cell Therapeutics, Inc.(NYSEAM:LCTX) dropped from Russell Microcap Value Index CI
Lineage Cell Therapeutics, Inc.(NYSEAM:LCTX) added to Russell 2000 Index CI
Lineage Cell Therapeutics, Inc.(NYSEAM:LCTX) added to Russell 3000 Growth Index CI
Lineage Cell Therapeutics, Inc.(NYSEAM:LCTX) added to Russell 2000 Dynamic Index CI
Chart Lineage Cell Therapeutics, Inc.
More charts
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing cell therapies to address unmet medical needs. It designs, develops, and manufactures specialized human cells with anatomical and physiological functions which are similar or identical to cells found naturally in the human body. It has five allogeneic product candidates: OpRegen, OPC1, VAC2, ANP1, and PNC1. OpRegen is a retinal pigment epithelium (RPE) cell replacement therapy in a Phase IIa development for the treatment of geographic atrophy secondary to age-related macular degeneration (AMD). OPC1 is an oligodendrocyte progenitor cell therapy in a Phase I/IIa development for the treatment of acute spinal cord injuries (SCI); VAC is a dendritic cell therapy produced from Lineages VAC technology platform for immuno-oncology and infectious disease, in Phase I clinical development for the treatment of non-small cell lung cancer.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.11 USD
Average target price
5.4 USD
Spread / Average Target
+386.49%
Consensus
  1. Stock
  2. Equities
  3. Stock Lineage Cell Therapeutics, Inc. - Nyse
  4. News Lineage Cell Therapeutics, Inc.
  5. Lineage Cell Therapeutics : Noble Capital Initiates Coverage on Lineage Cell Therapeutics With Outperform Rating, $8 Price Target
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW